Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Jerome R Lechien, Carlos M Chiesa-Estomba, Daniele R De Siati, Mihaela Horoi, Serge D Le Bon, Alexandra Rodriguez, Didier Dequanter, Serge Blecic, Fahd El Afia, Lea Distinguin, Younes Chekkoury-Idrissi, Stéphane Hans, Irene Lopez Delgado, Christian Calvo-Henriquez, Philippe Lavigne, Chiara Falanga, Maria Rosaria Barillari, Giovanni Cammaroto, Mohamad Khalife, Pierre Leich, Christel Souchay, Camelia Rossi, Fabrice Journe, Julien Hsieh, Myriam Edjlali, Robert Carlier, Laurence Ris, Andrea Lovato, Cosimo De Filippis, Frederique Coppee, Nicolas Fakhry, Tareck Ayad, Sven Saussez, Jerome R Lechien, Carlos M Chiesa-Estomba, Daniele R De Siati, Mihaela Horoi, Serge D Le Bon, Alexandra Rodriguez, Didier Dequanter, Serge Blecic, Fahd El Afia, Lea Distinguin, Younes Chekkoury-Idrissi, Stéphane Hans, Irene Lopez Delgado, Christian Calvo-Henriquez, Philippe Lavigne, Chiara Falanga, Maria Rosaria Barillari, Giovanni Cammaroto, Mohamad Khalife, Pierre Leich, Christel Souchay, Camelia Rossi, Fabrice Journe, Julien Hsieh, Myriam Edjlali, Robert Carlier, Laurence Ris, Andrea Lovato, Cosimo De Filippis, Frederique Coppee, Nicolas Fakhry, Tareck Ayad, Sven Saussez

Abstract

Objective: To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection.

Methods: Patients with laboratory-confirmed COVID-19 infection were recruited from 12 European hospitals. The following epidemiological and clinical outcomes have been studied: age, sex, ethnicity, comorbidities, and general and otolaryngological symptoms. Patients completed olfactory and gustatory questionnaires based on the smell and taste component of the National Health and Nutrition Examination Survey, and the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS).

Results: A total of 417 mild-to-moderate COVID-19 patients completed the study (263 females). The most prevalent general symptoms consisted of cough, myalgia, and loss of appetite. Face pain and nasal obstruction were the most disease-related otolaryngological symptoms. 85.6% and 88.0% of patients reported olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders (p < 0.001). Olfactory dysfunction (OD) appeared before the other symptoms in 11.8% of cases. The sQO-NS scores were significantly lower in patients with anosmia compared with normosmic or hyposmic individuals (p = 0.001). Among the 18.2% of patients without nasal obstruction or rhinorrhea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males (p = 0.001).

Conclusion: Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, who may not have nasal symptoms. The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection.

Keywords: Anosmia; COVID; COVID-19; Coronavirus; Dysgeusia; ENT; Gustatory; Hyposmia; Infection; Loss; Olfaction; Olfactory; SARS-CoV-2; Smell; Taste.

Conflict of interest statement

The authors have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Comorbidities of COVID-19 patients. The ordinate axis consists of percentages of patients with comorbidities in the cohort. Respiratory insufficiency consists of COPD, emphysema, fibrosis, or other chronic disease associated with a respiratory insufficiency. Neurological diseases include Parkinson disease, myasthenia, multiple sclerosis, and all degenerative diseases. COPD chronic obstructive pulmonary disease, CRS chronic rhinosinusitis, GERD gastroesophageal reflux disease
Fig. 2
Fig. 2
General symptoms associated with COVID-19 infection. The ordinate axis consists of percentages of patients with such symptoms associated with the infection
Fig. 3
Fig. 3
Pattern of recovery time for patients with olfactory dysfunction. The ordinate axis consists of percentages of patients. The patients with hyposmia or anosmia had the following recovery times a 1–4 days (33.0%), 5–8 days (39.6%), 9–14 days (24.2%), and more than 15 days (3.3%). The patients with anosmia had the following recovery times b 1–4 days (20.3%), 5–8 days (47.5%), 9–14 days (28.8%), and more than 15 days (3.4%)
Fig. 4
Fig. 4
Therapeutic strategies for COVID-19 infection (a) and olfactory dysfunction (b)

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, MacLaren G, Brodie D, Shekar K. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 doi: 10.1016/s2213-2600(20)30121-1.
    1. Wu YC, Chen CS, Chan YJ. Overview of the novel coronavirus (2019-nCoV): the pathogen of severe specific contagious pneumonia (SSCP) J Chin Med Assoc. 2020 doi: 10.1097/JCMA.0000000000000270.
    1. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020 doi: 10.1001/jama.2020.3204.
    1. Wan S, Xiang Y, Fang W, Zheng Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020 doi: 10.1002/jmv.25783.
    1. Suzuki M, Saito K, Min WP, Vladau C, Toida K, Itoh H, Murakami S. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007;117(2):272–277. doi: 10.1097/01.mlg.0000249922.37381.1e.
    1. van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol. 2015;235(2):277–287. doi: 10.1002/path.4461.
    1. Ayad T, Stephenson K, Smit D, et al. Young Otolaryngologists of International Federation of Oto-rhino-laryngological Societies (YO-IFOS) committees. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135(5S):S61–S65. doi: 10.1016/j.anorl.2018.08.004.
    1. Mattos JL, Edwards C, Schlosser RJ, Hyer M, Mace JC, Smith TL, Soler ZM. A brief version of the questionnaire of olfactory disorders in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(10):1144–1150. doi: 10.1002/alr.22392.
    1. Bhattacharyya N, Kepnes LJ. Contemporary assessment of the prevalence of smell and taste problems in adults. Laryngoscope. 2015;125(5):1102–1106. doi: 10.1002/lary.24999.
    1. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. doi: 10.1056/NEJMc2001737.
    1. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. MedRXiv. 2020 doi: 10.1101/2020.02.22.20026500.
    1. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe. 2013;13(4):379–393. doi: 10.1016/j.chom.2013.03.010.
    1. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–7275. doi: 10.1128/JVI.00737-08.
    1. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424. doi: 10.1084/jem.20050828.
    1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020 doi: 10.1002/jmv.25728.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al (2020) Clinical characteristics of 2019 novel coronavirus infection in China. Medrxiv
    1. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol. 2020;92(4):455–459. doi: 10.1002/jmv.25688.
    1. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.
    1. Li W, Zhang C, Sui J, Kuhn JH, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24(8):1634–1643. doi: 10.1038/sj.emboj.7600640.
    1. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6:11. doi: 10.1038/s41421-020-0147-1.
    1. Lefèvre N, Corazza F, Valsamis J, Delbaere A, De Maertelaer V, Duchateau J, Casimir G. The number of X chromosomes influences inflammatory cytokine production following toll-like receptor stimulation. Front Immunol. 2019;10:1052. doi: 10.3389/fimmu.2019.01052.
    1. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54(26):1–30. doi: 10.4193/Rhino16.248.
    1. Gudziol H, Guntinas-Lichius O. Electrophysiologic assessment of olfactory and gustatory function. Handb Clin Neurol. 2019;164:247–262. doi: 10.1016/B978-0-444-63855-7.00016-2.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する